JPRN-jRCT2080220407
Unknown
Phase 3
A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer
ConditionsBreast Cancer Metastasis
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Breast Cancer Metastasis
- Sponsor
- AstraZeneca
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Genders Eligible for Study: Female
- •Inclusion Criteria:
- •Biopsy confirmation of breast cancer. Evidence of breast cancer that is not considered amenable to curative treatment.
- •Postmenopausal women. Written informed consent to participate in the study.
Exclusion Criteria
- •Previous treatment with hormonal therapy unless that therapy was tamoxifen for adjuvant breast cancer. The use of tamoxifen must have ceased at least one year before this study.
- •Previous treatment with Faslodex. Any existing serious disease, illness, or condition that will prevent participation or compliance with the study procedures.
- •Treatment with an investigational or non\-approved drug within one month of then start of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation.MedDRA version: 20.0 Level: PT Classification code 10029888 Term: Obliterative bronchiolitis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2018-001747-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)80
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Double-Blind Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced Non CCR5-Tropic HIV-1 Infected SubjectEUCTR2004-001779-20-ITPfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582192
Completed
Phase 2
The survival and quality of life benefits of melatonin when administered to cancer patients at the optimal time of dayThe affects of adjuvant melatonin on the outcomes of stage III and IV non small cell lung cancer patientsCancerISRCTN16419921Cancer Treatment Centers of America®90
Completed
Phase 3
A phase III study of ONO-4538(ONO-4538-52/TASUKI-52)JPRN-jRCT2080223505ONO PHARMACEUTICAL CO.,LTD.530
Recruiting
Not Applicable
Double-blind Randomized Multi-center Trial Regarding the Effects of Solution for Gemcitabine on Frequency and Degree of Vascular Pain in Patients with CancerJPRN-UMIN000001827Tohoku University Translational Research Center90